Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.
Dunne PD, et al. Among authors: bingham v.
Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2.
Oncotarget. 2018.
PMID: 29568398
Free PMC article.